The lung cancer therapeutic space is fast-paced and hopeful, with new therapies approved for gene mutations allowing for personalized medicine and an evolving understanding of disease biology. And dynamic it must be, with lung cancer the most commonly occurring cancer worldwide, accounting for 12.4% of total new cases.
AstraZeneca’s Stable Of Lung Cancer Therapies
-
Tagrisso (osimertinib)
In March, the FDA approved Johnson & Johnson’s Rybrevant (mivantamab) with chemotherapies carboplatin and pemetrexed for the first-line treatment...
